Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...

Moderna said its experimental vaccine for cytomegalovirus failed in a key trial, a significant setback for a company already ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

In the largest synthesis to date, researchers reviewed 155 studies linking viral infections, including influenza, SARS-CoV-2, ...

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital cytomegalovirus (CMV) infections – once ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

When Gideon Dobson's parents need a mental health break, he stays at Ryan House, where children with "life-limiting" medical ...

Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.